Background illustration for clinical trials search

Paid Clinical Trials Nashville

Discover 1,239 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

for
Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Location: Nashville TN, Chapel Hill NC, Denver CO
Sponsor: Iovance Biotherapeutics, Inc.

Sex: All

Age: 18 - 70

Code: NCT06940739

Phase 1, Phase 2, Recruiting

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

for
NSCLC (Advanced Non-small Cell Lung Cancer)
Location: Nashville TN, Chicago IL, Durham NC, Detroit MI,
Sponsor: BlossomHill Therapeutics

Sex: All

Age: 18+

Code: NCT06706076

Phase 1, Phase 2, Recruiting

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

for
Small Cell Lung Cancer (SCLC ),
Location: Nashville TN, St Louis MO, Dallas TX, Houston TX,
Sponsor: Moonlight Bio, Inc

Sex: All

Age: 18+

Code: NCT07488923

Phase 1, Recruiting

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

for
Melanoma (Skin Cancer),
Location: Nashville TN, Cincinnati OH, Detroit MI, Fairway KS,
Sponsor: Aminex Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07287917

Phase 1, Phase 2, Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Location: Nashville TN, St Louis MO, Chicago IL, Chapel Hill NC,
Sponsor: Verastem, Inc.

Sex: All

Age: 18+

Code: NCT07644559

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

for
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,
Location: Nashville TN, Iowa City IA, Wichita KS, Dallas TX,
Sponsor: TORL Biotherapeutics, LLC

Sex: All

Age: 18+

Code: NCT07439653

Phase 1, Phase 2, Recruiting

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

for
Triple Negative Breast Cancer (TNBC)
Location: Nashville TN, Grand Rapids MI
Sponsor: Immunomic Therapeutics, Inc.

Sex: Female

Age: 18+

Code: NCT07652242

Phase 1, Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

for
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell,
Location: Nashville TN, Atlanta GA, Columbus OH, Milwaukee WI,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07226843

Phase 1, Recruiting

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

for
Advanced NRAS-Mutant Melanoma,
Location: Nashville TN, Grand Rapids MI, Fairfax VA, New York NY,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07584226

Phase 1, Recruiting

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Location: Nashville TN, Cincinnati OH, Durham NC, Pittsburgh PA,
Sponsor: Amgen

Sex: Male

Age: 18+

Code: NCT07493512

Phase 1, Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

for
Lymphoma
Location: Nashville TN, St Louis MO, Columbus OH, Chicago IL,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT07015242

Phase 2, Recruiting

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

for
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer,
Location: Nashville TN, Knoxville TN, Birmingham AL, St Louis MO,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07154290

Phase 2, Recruiting

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

for
Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma,
Location: Nashville TN
Sponsor: AvenCell Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07284433

Phase 1, Phase 2, Recruiting

Study in Advanced Solid Tumor Patients

for
Advanced Solid Tumor
Location: Nashville TN, Houston TX, San Antonio TX,
Sponsor: Callio Therapeutics

Sex: All

Age: 18+

Code: NCT07300943

Phase 1, Phase 2, Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

for
Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer,
Location: Nashville TN, Orlando FL, Houston TX
Sponsor: Phrontline Biopharma

Sex: All

Age: 18+

Code: NCT07181473

Phase 1, Recruiting

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

for
Metastatic Malignant Neoplasm
Location: Nashville TN, Fairfax VA, Baltimore MD, Houston TX,
Sponsor: NextPoint Therapeutics, Inc.

Sex: All

Age: 19+

Code: NCT07563829

Phase 1, Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

for
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Location: Denver CO, Nashville TN, Cleveland OH, Jacksonville FL,
Sponsor: Pierre Fabre Medicament

Sex: All

Age: 18+

Code: NCT04913285

Phase 1, Recruiting

A Study of CTD402 in T-ALL/LBL Patients

for
Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Location: Nashville TN, Chicago IL, Rochester MN, Houston TX,
Sponsor: Imviva Bio

Sex: All

Age: 1+

Code: NCT07070219

Phase 1, Phase 2, Recruiting

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

for
Advanced Solid Tumor
Location: Nashville TN, Scottsdale AZ
Sponsor: Strand Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT07751042

Phase 1, Phase 2, Recruiting

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Location: Nashville TN, Cleveland OH, Pittsburgh PA,
Sponsor: Amgen

Sex: Male

Age: 18+

Code: NCT07140900

Phase 1, Recruiting